Systematic analysis of adverse reaction signals induced by leflunomide, upadacitinib, and baricitinib in the treatment of rheumatoid arthritis: a FAERS database analysis - Report - MDSpire
Advertisement
Comprehensive Evaluation of Adverse Event Reports Linked to Leflunomide, Upadacitinib, and Baricitinib in Rheumatoid Arthritis Management: Insights from the FAERS Database
Clinical Report: Adverse Event Reports for Leflunomide, Upadacitinib, Baricitinib
Overview
This study analyzed adverse drug events (ADEs) associated with leflunomide, upadacitinib, and baricitinib in rheumatoid arthritis treatment using the FAERS database. A total of 10,445, 27,433, and 2,638 ADE reports were identified for leflunomide, upadacitinib, and baricitinib, respectively, from January 2004 to December 2024.
Background
Rheumatoid arthritis (RA) is a chronic inflammatory disease that significantly impacts patient quality of life. Leflunomide, upadacitinib, and baricitinib are commonly used treatments.
Data Highlights
Drug
ADE Reports
Peak Year
Leflunomide
10,445
2020
Upadacitinib
27,433
2022
Baricitinib
2,638
2019
Key Findings
Baricitinib-related ADEs included infections and blood disorders.
Leflunomide-related ADEs involved hepatic disorders and hereditary diseases.
Upadacitinib-related ADEs included surgical and medical procedures.
The number of ADE reports for each drug varied significantly over the years.
Clinical Implications
Clinicians should be aware of the specific ADEs associated with leflunomide, upadacitinib, and baricitinib when prescribing these medications. Continuous monitoring of ADEs can inform safer prescribing practices and improve patient outcomes.
Conclusion
This evaluation of ADEs linked to leflunomide, upadacitinib, and baricitinib provides insights for healthcare professionals managing rheumatoid arthritis.
